1Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Haematopoietic and Lymphoid Tissue. IARC Press. Lyon,2001. 被引量：1
2The non-Hodgkin's Lymphoma Classification Project: a clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's Lymphoma. Blood, 1997,89: 3909. 被引量：1
3NCCN Clinical Practice Guidelines in Oncology-Non-Hodgkin's Lymphomas Guideline, 2007. 被引量：1
4Ott G, Kalla J, Hanke A, et al. The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological feature. Leuk Lymphoma, 1998,32 : 55. 被引量：1
5Mac Lennan KA,Bennett MH, Vaughan Hudson B, et al. Diagnosis and grading of nodular sclerosing Hodgkin's disease:a study of 2190 patients. Int Rev Exp Pathol, 1992, 33:27. 被引量：1
6Haybittle JL, Hayhoe FG, Easterling MJ, et al. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet, 1985,1:967. 被引量：1
7Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade Lymphoma. Semin Oncol,2002,29:36. 被引量：1
8Del Principe MI, Del Poeta G, Buccisauo F, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood, 2006,108 : 853. 被引量：1
9Falini B, Pileri S, Zinzani P1, et al. ALK lymphomas: clinicopathological findings and outcome. Blood, 1999,99 : 3509. 被引量：1
10Falini B, Pulford K, Pucciarini A, et al, Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood, 1999,94: 3509. 被引量：1
